Evidence Hub

Teriparatide therapy for medication-related osteonecrosis of the jaw: case report and literature review

M. Mohamed, W. Gunasekera, D. Glew, C. Bell, A. Bhalla

Clinical medicine (London), 2022

3 citations

Abstract

We present the case of an 81-year-old lady with severe osteoporosis and ischaemic heart disease, who had been on Alendronate 70mg weekly for 3 years when she had a tooth extraction. 3 months later she presented to Maxillofacial Surgery with non-healing extraction sites, facial pain and erythema and a malodorous discharging sub-mantle sinus. She received a diagnosis of stage 3 MRONJ confirmed on Orthodentogram and CT scan. She had Proteus mirabilis on tissue culture. She had no history of osteosarcoma or local radiotherapy. Discussion: The biological rationale for the benefit of Teriparatide which is a recombinant Parathyroid hormone (rPTH) could lay in the fact that rPTH increases the proliferation of T-cells thereby increasing Wnt-10b production and enhancing osteoblast differentiation. 6 Teriparatide enhances osteoblast RANKL production to drive osteogenesis and augments osteoclast recruitment. 7 These cells are pivotal to bone healing and a prerequisite for the anabolic effect of Teriparatide on osteoblasts.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free